# JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

> **NCT06416410** · PHASE3 · RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 392 (estimated)

## Conditions studied

- Advanced Non-squamous Non-small-cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer

## Interventions

- **DRUG:** JAB-21822
- **DRUG:** Tislelizumab
- **DRUG:** JAB-3312
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06416410
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06416410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06416410, "JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06416410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*